# 25 Hydroxyvitamin D and Cytokine Profile in Patients With Relapsing-Remitting Multiple Sclerosis

**Authors:** Georgi S Slavov, Mariya G Manova, Ivanka I Kostadinova

PMC · DOI: 10.7759/cureus.61534 · 2024-06-02

## TL;DR

This study examines how vitamin D and cytokine levels change in patients with relapsing-remitting multiple sclerosis during relapse and remission phases.

## Contribution

The study identifies specific cytokine profiles and vitamin D correlations during relapse and remission in multiple sclerosis patients.

## Key findings

- During relapse, interferon-gamma levels were significantly higher compared to remission.
- During remission, anti-inflammatory cytokines TGF-β and IL4 increased compared to relapse.
- A moderate relationship was found between IL17 and 25-hydroxyvitamin D during exacerbation.

## Abstract

In experimental allergic encephalomyelitis, the severity of the deficiency is associated with the loss of axons, and it is likely that cytotoxic T-cells 8 (CD8 T) play an important role. In relapsing-remitting multiple sclerosis, there is a correlation between the inflammatory activity in the lesion and the transection of axons. To understand the pathological mechanisms, it is important to evaluate the changes in serum concentrations of pro- and anti-inflammatory cytokines during the disease course. A total of 46 patients and 40 healthy individuals participated in an open-label, prospective, case-control study from 2012 to 2014. The serum concentrations of cytokines were measured using enzyme-linked immunosorbent assay (ELISA). An immune imbalance was observed during relapse and remission phases compared to the control group. During relapse, the levels of interferon-gamma (IFN-γ) were significantly higher compared to those in remission (p=0.017). During remission, there was an improvement in the deficiency (p<0.001), and the anti-inflammatory cytokines transforming growth factor-beta (TGF-β) and interleukin 4 (IL4) increased compared to those in relapse (p=0.006; p=0.009). A correlation was found between the serum concentrations of tumor necrosis factor-alpha (TNF-α) and Expanded Disability Status Scale (EDSS) during relapse (correlation coefficient: 0.301; significance (Sig.) (2-tailed 0.042). During the exacerbation, there was a moderate relationship between interleukin 17 (IL17) and 25-hydroxyvitamin D (25(OH)D) (P (p-value (probability value) = 0.02)). TNF-α, IFN-γ, IL17, and TGF-β serum levels are criteria for evaluating immune inflammatory activity during relapse and remission periods.

## Linked entities

- **Proteins:** IL4 (interleukin 4)
- **Chemicals:** 25-hydroxyvitamin D (PubChem CID 5353325)
- **Diseases:** relapsing-remitting multiple sclerosis (MONDO:0005314)

## Full-text entities

- **Genes:** IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}
- **Diseases:** inflammatory (MESH:D007249), Relapsing-Remitting Multiple Sclerosis (MESH:D020529), experimental allergic encephalomyelitis (MESH:D004681)
- **Chemicals:** 25 Hydroxyvitamin D (MESH:C104450), 25(OH)D (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC11218926